InvestorsHub Logo
Followers 99
Posts 2761
Boards Moderated 2
Alias Born 02/10/2004

Re: None

Tuesday, 08/04/2020 5:19:47 PM

Tuesday, August 04, 2020 5:19:47 PM

Post# of 19499
Lantheus indicates the Flurpiridaz F-18 trial timeline has been extended due to COVID-19:

https://finance.yahoo.com/news/edited-transcript-lnth-oq-earnings-121431193.html

"Turning now to Flurpiridaz F 18, our novel PET cardiac imaging agent. Our development and commercialization partner, GE Healthcare, has informed us that the second Phase III trial continues. However, new patient enrollment has been delayed due to the impact of the pandemic. GE Healthcare intends to resume enrollment in this quarter and expects to complete enrollment by mid-2021, and, assuming regulatory approval, begin commercialization in early 2023."

"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854